Karo Bio Announces That Merck & Co., Inc. Plans To Proceed With Phase II Clinical Evaluation Of Candidate Compound

The Swedish biotech company Karo Bio (Reuters: KARO.ST) announced that Merck & Co., Inc., through an affiliate, plans to enter a clinical phase IIa trial with the collaboration’s lead investigational drug candidate, MK-6913, identified as part of their joint research collaboration. No milestone payment to Karo Bio is associated with the initiation of phase II clinical development.

source : www.medicalnewstoday.com

Related News:

• Subretinal Implant Restores Unprecedented Level Of Vision To Blind Patients
• Acucela And Otsuka Pharmaceutical Receive FDA Fast Track Designation For ACU-4429 In Patients With Dry AMD
• Impact Of Ethnicity On Primary Treatment Choice And Mortality In Men With Prostate Cancer: Data From CaPSURE
• Greater Infection Risk with Staples in Hip Surgery (CME/CE)
• SGO: No Lung CA Risk Seen with Estrogen (CME/CE)
• Patients With Long-Term Conditions Need Greater Support To Return To Work, England
• BrainPort Helps Blinded Soldier See With Tongue
• Insufficiency Fractures After Pelvic Radiotherapy In Patients With Prostate Cancer
• Greater Infection Risk with Staples in Hip Surgery
• SIR: ABI Flags Those Not Otherwise at Risk for CVD